Eficácia e seguran？a dos antipsicóticos atípicos nas demências: uma revis？o sistemática

objective: concerns have been raised about efficacy and adverse events of atypical antipsychotics in the treatment of behavioural and psychological symptoms of dementia (bpsd). this paper is an update on current evidence of this theme. methods: review of published meta-analysis and randomized placebo-controlled trials (rcts) in the last ten years. results: three meta-analysis and nine rcts were evaluated. evidence suggests that risperidone (1mg/day), olanzapine (5 to 10mg/day), and aripiprazole (2 to 15mg/day) are effective in treating aggression and/or bpsd overall; risperidone (1mg/day) reduces psychosis. adverse events were mainly somnolence, extrapyramidal symptoms, urinary tract infection or incontinence, and abnormal gait with drug treatment. atypical antipsychotics were associated with increased risk for cerebrovascular adverse events and mortality in elderly patients with dementia. conclusion: low doses of risperidone, olanzapine, and aripiprazole are effective in treating aggression and/or bpsd overall, and risperidone reduces psychosis associated with dementia. in view of the increased risk of cerebrovascular adverse events and mortality, the use of atypical antipsychotics in individuals with dementia should be reserved for patients with moderate/severe behavioural symptoms.